Towards epigenetic regulation of triple-negative breast cancer via ligand-mediated nanoparticles

Nanomedicine (Lond). 2023 Mar;18(6):541-554. doi: 10.2217/nnm-2023-0006. Epub 2023 May 11.

Abstract

Aims: Develop and analyze triple-negative breast cancer targeted nanoparticles loaded with the demethylating agent decitabine. Materials & methods: The polymers were synthesized by ring-opening polymerization of D,L-lactide and formulated into nanoparticles via emulsion-evaporation method. The nanoparticles were characterized by physicochemical analysis as well as in vitro using breast cancer cell lineages. Results & conclusion: The targeted nanoparticles exhibited a hydrodynamic diameter of 75 ± 12 nm, zeta potential -6.3 ± 0.2 mV and spherical morphology, and displayed greater in vitro accumulation into MDA-MB-231 (triple-negative breast cancer cell-line) compared with MCF7 and HB4A cell lineages as verified by fluorescence confocal microscopy and significant demethylating effects via ADAM33 screening by PCR.

Keywords: EGF; epigenetic; nanoparticles; triple-negative breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins
  • Breast Neoplasms*
  • Cell Line, Tumor
  • Epigenesis, Genetic
  • Female
  • Humans
  • Ligands
  • Nanoparticles* / chemistry
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / genetics

Substances

  • Ligands
  • ADAM33 protein, human
  • ADAM Proteins